Prohibitin 3′ UTR C/T polymorphism genotype distribution among cases and controls
| Group | CC | CT | TT | TT or CT | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) | P valuea | N (%) | P valuea (OR, 95% CI) | N (%) | P valuea (OR, 95% CI) | N (%) | P valuea (OR, 95% CI) | |||||
| Controls | 170 (71.4) | 61 (25.6) | 7 (3.0) | 68 (28.6) | ||||||||
| All breast cancer | 188 (64.6) | 1.00 | 93 (32.0) | 0.1 (1.3, 0.9–2.0) | 10 (3.4) | 0.6 (1.3, 0.5–3.5) | 103 (35.4) | 0.1 (1.3, 0.9–2.0) | ||||
| Under 40 BrCab | 142 (68.3) | 1.00 | 59 (28.4) | 0.5 (1.2, 0.7–1.7) | 7 (3.3) | 0.8 (1.2, 0.4–3.5) | 66 (31.7) | 0.5 (1.2, 0.7–1.7) | ||||
| Familialc BrCa | 123 (64.1) | 1.00 | 65 (33.8) | 0.1 (1.5, 0.9–2.2) | 4 (2.1) | 0.7 (0.7, 0.2–2.8) | 69 (35.9) | 0.1 (1.4, 0.9–2.1) | ||||
a Fisher’s exact test (two-sided) for the relevant genotype using the CC genotype as reference. The ORs and 95% CIs are shown in brackets.
b BrCa, breast cancer.
c Family history is defined as two or more cases of breast cancer reported in first or second degree female relatives or bilateral breast cancer.